Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $230.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target boosted by Truist Financial from $220.00 to $230.00 in a report released on Monday,Benzinga reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other equities analysts also recently commented on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $219.00 price objective (up previously from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. Needham & Company LLC boosted their target price on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research note on Monday. Robert W. Baird raised their price target on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Finally, Bank of America boosted their price objective on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $205.67.

Jazz Pharmaceuticals Stock Up 5.2%

Shares of NASDAQ:JAZZ opened at $170.81 on Monday. The firm has a market capitalization of $10.38 billion, a PE ratio of -28.14, a price-to-earnings-growth ratio of 0.72 and a beta of 0.27. The business has a 50 day simple moving average of $165.51 and a two-hundred day simple moving average of $138.87. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $182.99. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 5,319 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $182.06, for a total value of $968,377.14. Following the completion of the transaction, the chief accounting officer owned 7,012 shares of the company’s stock, valued at $1,276,604.72. The trade was a 43.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Robert Iannone sold 7,159 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $168.26, for a total value of $1,204,573.34. Following the sale, the executive vice president owned 72,628 shares of the company’s stock, valued at approximately $12,220,387.28. This represents a 8.97% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 123,791 shares of company stock worth $21,991,850. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC boosted its position in Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 234 shares in the last quarter. Hilltop National Bank purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $36,000. Hantz Financial Services Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 297 shares in the last quarter. Danske Bank A S purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $40,000. Finally, Quent Capital LLC bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $44,000. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.